TCTMD

Philips Response to ResMed Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea and Chronic Heart Failure

On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...
FierceBiotech

ResMed launches new bi-level sleep apnea device as CPAP alternative

As Philips reaches a consent decree agreement with the FDA that will temporarily suspend its sales of sleep therapy devices in the U.S., competitor ResMed, meanwhile, is ramping up its product ...
Yahoo Finance

ResMed: Positive CAT-HF Study Results to Drive ASV Sales

Primary results from ResMed Inc.’s RMD CAT-HF trial showcased the significance of adaptive servo-ventilation (ASV) therapy in the treatment of heart failure (HF). Data were presented at the European ...
Newswire

New ResMed-sponsored Study Shows Promising Treatment Option for Patients with Untreated Central Sleep Apnea

- Largest-ever analysis of patients with treatment-emergent central sleep apnea shows switching from CPAP to ASV significantly improves compliance - Study highlights the need to consider therapeutic ...
FierceBiotech

Philips cautions on cardio mortality after ResMed sleep apnea data, intros cardiac imaging tool

Royal Philips ($PHG) said it is working with ResMed ($RMD) to analyze study data from mid-May showing that the latter company's Adaptive Servo-Ventilation (ASV ...